capecitabine has been researched along with Response Evaluation Criteria in Solid Tumors in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Ariizumi, H; Fujita, KI; Hirasawa, Y; Hisamatsu, A; Ikusue, T; Ishida, H; Ishiguro, T; Kobayashi, K; Kubota, Y; Matsumoto, N; Ohkuma, R; Sekido, M; Shimada, K; Toshima, H; Tsunoda, T | 1 |
| Friberg, LE; Karlsson, MO; Koopman, M; Netterberg, I; Punt, CJA; Terstappen, LWMM | 1 |
| Adelberg, D; Bang, YJ; Bhagia, P; Fuchs, CS; Janjigian, YY; Li, K; Qin, SK; Tabernero, J; Van Cutsem, E | 1 |
| Aalbers, AGJ; Bakkers, C; Boerma, D; Brandt-Kerkhof, ARM; Bremers, AJA; Buffart, TE; Burger, JWA; Creemers, GM; de Groot, DJA; de Hingh, IHJT; de Reuver, PR; Dijkgraaf, MGW; Fijneman, RJA; Hemmer, PHJ; Kok, NFM; Koopman, M; Kranenburg, O; Kruijff, S; Kusters, M; Lahaye, MJ; Los, M; Madsen, EVE; Nederend, J; Nienhuijs, SW; Punt, CJA; Rovers, KP; Snaebjornsson, P; Tanis, PJ; Thijs, AMJ; Tuynman, JB; van 't Erve, I; van Grevenstein, WMU; van Meerten, E; Verheul, HMW; Versteeg, KS; Wiezer, MJ; Witkamp, AJ | 1 |
| Bloemen, JG; Burger, JWA; Cnossen, JS; Creemers, GJ; Nederend, J; Nieuwenhuijzen, GAP; Peulen, HMU; Rutten, HJT; Schaap, DP; van den Berg, K; van Lijnschoten, G; Voogt, ELK; Willems, J | 1 |
| Hayashi, T; Kamiya, A; Katai, H; Otsuki, S; Sekine, S; Wada, T; Yamagata, Y; Yoshikawa, T | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Arriaga, L; Babiera, GV; Buchholz, TA; Cohen, EN; Fang, P; Gao, H; Hoffman, K; Le-Petross, H; Middleton, LP; Perkins, GH; Reuben, JM; Smith, BD; Strom, EA; Tereffe, W; Valero, V; Woodward, WA | 1 |
| Arnold, D; Elias, SG; Goey, KKH; Hegewisch-Becker, S; Hinke, A; Koopman, M; Punt, CJA; van Oijen, MGH | 1 |
| Bachelot, T; Chan, S; Farci, D; Han, HS; Jerusalem, G; Kong, A; Massacesi, C; Mouhaër, SL; Pistilli, B; Pluard, T; Robinson, D; Saura, C; Tomaso, ED; Urban, P; Urruticoechea, A | 1 |
| Brady, WE; Christensen, H; Dark, G; Feeney, A; Frumovitz, M; Ganesan, R; Gershenson, DM; Gore, M; Hackshaw, A; Kehoe, S; Ledermann, J; Lord, R; Mackean, M; McCluggage, WG; Montes, A; Penson, RT; Perren, T; Reed, N; Rustin, G; Summers, J; Wilkinson, N; Zaino, R | 1 |
| Álvarez, R; Cubillo, A; de Vicente, E; García, E; Hernando, O; Hidalgo, M; López-Ríos, F; Perea, S; Plaza, C; Quijano, Y; Rodriguez-Pascual, J; Rubio, C; Sanchez, G | 1 |
| Bang, S; Cheon, YK; Cho, CM; Cho, KB; Choi, HS; Chung, MJ; Kang, DH; Kim, CD; Kim, DU; Kim, HG; Kim, HJ; Kim, JK; Kim, TH; Kim, YT; Lee, DK; Lee, HS; Lee, SH; Moon, J; Moon, JH; Noh, MH; Park, JY; Park, SW; Shin, HJ; Song, SY | 1 |
9 trial(s) available for capecitabine and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Oxaliplatin; Randomized Controlled Trials as Topic; Response Evaluation Criteria in Solid Tumors; Stomach Neoplasms; Treatment Outcome | 2021 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Fluorouracil; Humans; Hyperthermic Intraperitoneal Chemotherapy; Leucovorin; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Perioperative Period; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors | 2021 |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prospective Studies; Radiotherapy Dosage; Response Evaluation Criteria in Solid Tumors; Triple Negative Breast Neoplasms | 2017 |
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Maintenance Chemotherapy; Male; Meta-Analysis as Topic; Response Evaluation Criteria in Solid Tumors; Survival Rate; Watchful Waiting | 2017 |
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Trastuzumab | 2018 |
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Follow-Up Studies; Humans; Internationality; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Progression-Free Survival; Quality of Life; Response Evaluation Criteria in Solid Tumors; Survival Rate; Young Adult | 2019 |
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Decision-Making; Colorectal Neoplasms; Decision Trees; Disease-Free Survival; DNA Mutational Analysis; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinase; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
5 other study(ies) available for capecitabine and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Japan; Male; Middle Aged; Oxaliplatin; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Tissue Distribution | 2020 |
Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cell Count; Cetuximab; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplastic Cells, Circulating; Oxaliplatin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Risk Assessment; Tumor Burden | 2020 |
Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Case-Control Studies; Dose Fractionation, Radiation; Fascia; Female; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome; Tumor Burden; Watchful Waiting | 2021 |
Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Biomarkers; Capecitabine; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Trastuzumab | 2022 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |